Literature DB >> 17454609

Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.

Angelo Michele Carella, Samantha Biasco, Sandro Nati, Angela Congiu, Enrica Lerma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454609     DOI: 10.1080/10428190601094362

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies.

Authors:  Noa Granot; Andrew R Rezvani; Barbara S Pender; Barry E Storer; Brenda M Sandmaier; Rainer Storb; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-18       Impact factor: 5.742

2.  Rippled skin, fasciitis, and joint contractures.

Authors:  Asha R Patel; Daniele Avila; Harry L Malech; Steven Z Pavletic; Larry Yao; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2008-12       Impact factor: 11.527

Review 3.  Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.

Authors:  Jacopo Olivieri; Sabrina Coluzzi; Imma Attolico; Attilio Olivieri
Journal:  ScientificWorldJournal       Date:  2011-10-25

Review 4.  The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.

Authors:  Ruben Rhoades; Sameh Gaballa
Journal:  Biomedicines       Date:  2017-10-17

5.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.